Tolfenaminsure

Bezeichnung:Tolfenaminsure

CAS-Nr13710-19-5

Englisch Name:Tolfenamic acid

CBNumberCB6365693

SummenformelC14H12ClNO2

Molgewicht261.7

MOL-Datei13710-19-5.mol

Synonyma

Tolfenaminsure

Tolfenaminsure physikalisch-chemischer Eigenschaften

Schmelzpunkt	210-214°C
Siedepunkt	405.4±40.0 °C(Predicted)
Dichte	1.2037 (rough estimate)
Brechungsindex	1.5270 (estimate)
storage temp.	2-8°C
Löslichkeit	Practically insoluble in water, soluble in dimethylformamide, sparingly soluble in ethanol and in methylene chloride. It dissolves in dilute solutions of alkali hydroxides.
Aggregatzustand	Solid
pka	3.66±0.36(Predicted)
Farbe	White to Off-White
Wasserlöslichkeit	Soluble in water (slightly), acetone (~10 mg/ml), DMSO (52 mg/ml at 25°C), methanol (~10 mg/ml) and ethanol (50 mg/ml).
Merck	14,9513
InChIKey	YEZNLOUZAIOMLT-UHFFFAOYSA-N
CAS Datenbank	13710-19-5(CAS DataBase Reference)
EPA chemische Informationen	Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]- (13710-19-5)

Sicherheit

Kennzeichnung gefährlicher	Xn
R-Sätze:	22
RIDADR	UN 2811 6.1/PG 3
WGK Germany	3
RTECS-Nr.	CB2687500
HazardClass	6.1
PackingGroup	III
HS Code	29224919

Gefahreninformationscode (GHS)

Tolfenamic acid Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R22:Gesundheitsschädlich beim Verschlucken.
Chemische Eigenschaften
White Solid
Verwenden
Tolfenamic acid is a non-steroidal anti-inflammatory agent. It interferes with synthesis of β-amyloid precursor protein, and thus Aβ peptides, by promoting degradation of an essential transcription factor. It inhibits fMLP- and A23187-induced Ca2+ influx in human PMNL with an IC50 value of approximately 20 μM.
Verwenden
Non-steroidal anti-inflammatory drugs (NSAIDs).
Verwenden
A non steroidal anti-inflammatory agent found to inhibit COX-2 isoenzymes
Verwenden
Amidated GRF fragment equipotent to GRF in release of somatotropin from anterior pituitary
Verwenden
antiinflammatory, analgesia
Definition
ChEBI: An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 3-chloro-2-methylphenyl group. Tolfenamic acid is used specifically for relieving the pain of migraine. It also shows anticancer activity.
Allgemeine Beschreibung
Tolfenamic Acid is an anthranilic acid derivative and a non-steroidal anti-inflammatory drug (NSAID). Its applications in treating pancreatic, esophageal, colorectal and lung cancer is being investigated.
Biochem/physiol Actions
Non-steroidal anti-inflammatory agent. Interferes with synthesis of β-amyloid precursor protein, and thus Aβ peptides, by promoting degradation of an essential transcription factor.
Clinical Use
NSAID:
Treatment of migraine
Synthese
Tolfenamic acid is obtained by condensation of 2-chlorobenzoic acid with 3- chloro-2-methyl-phenylamine using CuBr2 in diethylenglycol dimethyl ether .
Veterinary Drugs and Treatments
Tolfenamic acid may be useful for the treatment of acute or chronic pain and/or inflammation in dogs and acute pain/inflammation in cats. In Europe, it is also approved for use in cattle.
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
Antibacterials: possibly increased risk of convulsions with quinolones.
Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban.
Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
Antidiabetic agents: effects of sulphonylureas enhanced.
Antiepileptics: possibly increased phenytoin concentration.
Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
Ciclosporin: may potentiate nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity
Stoffwechsel
Tolfenamic acid is metabolised in the liver; the metabolites and unchanged drug are conjugated with glucuronic acid. About 90
% of an ingested dose is excreted in the urine and the remainder in the faeces.

Tolfenaminsure Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

13710-19-5, Tolfenamic acid Verwandte Suche:

Send Inquriy